Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. The company is headquartered in Alameda, California and currently employs 4,500 full-time employees. The company went IPO on 2015-09-18. The firm's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. The company focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The firm sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
Follow-Up Questions
What is Penumbra Inc (PEN)'s P/E Ratio?
The P/E ratio of Penumbra Inc is 712.3214
Who is the CEO of Penumbra Inc?
Mr. Adam Elsesser is the Chairman of the Board of Penumbra Inc, joining the firm since 2004.
What is the price performance of PEN stock?
The current price of PEN is $235.08, it has increased 0% in the last trading day.
What are the primary business themes or industries for Penumbra Inc?
Penumbra Inc belongs to Health Care industry and the sector is Health Care
What is Penumbra Inc market cap?
Penumbra Inc's current market cap is $9.1B
Is Penumbra Inc a buy, sell, or hold?
According to wall street analysts, 20 analysts have made analyst ratings for Penumbra Inc, including 8 strong buy, 10 buy, 5 hold, 0 sell, and 8 strong sell
